-
ETNA-AF-Europe registry data on LIXIANA® (edoxaban) published in a leading cardiology journal highlights important clinical considerations for treating elderly patients with atrial fibrillationDaiichi Sankyo2023-11-09 20:59:05ETNA-AF-Europe registry data on LIXIANA® (edoxaban) published in a leading cardiology journal highlights
-
Daiichi Sankyo and AstraZeneca Enter New Global Development and Commercialization Collaboration for Daiichi Sankyo’s ADC DS-1062Daiichi Sankyo2020-08-03 09:16:13Daiichi Sankyo and AstraZeneca Enter New Global Development and Commercialization Collaboration for Daiichi
-
Real-world edoxaban VTE data show low rates of bleeding and VTE events reported after 12 months of edoxaban treatmentDaiichi Sankyo2023-11-09 14:58:41Real-world edoxaban VTE data show low rates of bleeding and VTE events reported after 12 months of edoxaban
-
EMA Validates and Grants Accelerated Assessment for Trastuzumab Deruxtecan for the Treatment of HER2 Positive Metastatic Breast CancerDaiichi Sankyo2023-11-09 20:58:33EMA Validates and Grants Accelerated Assessment for Trastuzumab Deruxtecan for the Treatment of HER2 Positive
-
Daiichi Sankyo’s SANTORINI study gets underway, investigating cholesterol care across EuropeDaiichi Sankyo2023-11-09 20:56:10Daiichi Sankyo’s SANTORINI study gets underway, investigating cholesterol care across Europe
-
Daiichi Sankyo Announces Clinical Research Collaboration to Evaluate DS-1062 in Combination with KEYTRUDA® (pembrolizumab) in Metastatic Non-Small Cell Lung CancerDaiichi Sankyo2023-11-09 20:56:21Daiichi Sankyo Announces Clinical Research Collaboration to Evaluate DS-1062 in Combination with KEYTRUDA®
-
ENHERTU® Demonstrated Meaningful Clinical Activity in Patients with HER2 Mutant Non-Small Cell Lung Cancer in Interim Analysis of Phase 2 DESTINY-Lung01 TrialDaiichi Sankyo2023-11-09 20:56:34ENHERTU® Demonstrated Meaningful Clinical Activity in Patients with HER2 Mutant Non-Small Cell Lung Cancer in
-
ENHERTU® Achieved a Tumor Response Rate of 45.3% in Patients with HER2 Positive Metastatic Colorectal Cancer in Phase 2 DESTINY-CRC01 TrialDaiichi Sankyo2023-11-09 20:56:43ENHERTU® Achieved a Tumor Response Rate of 45.3% in Patients with HER2 Positive Metastatic Colorectal Cancer
-
ENHERTU® Significantly Improved Tumor Response Rate and Overall Survival in HER2 Positive Metastatic Gastric Cancer in Pivotal Phase 2 DESTINY-Gastric01 TrialDaiichi Sankyo2023-11-09 20:56:52ENHERTU® Significantly Improved Tumor Response Rate and Overall Survival in HER2 Positive Metastatic Gastric
-
ENHERTU® Granted Orphan Drug Designation in the U.S. for Gastric CancerDaiichi Sankyo2023-11-09 20:57:08ENHERTU® Granted Orphan Drug Designation in the U.S. for Gastric Cancer
